UCL1684 (dibromide) is a small-conductance calcium-activated potassium (SK) channel blocker; it is effective in preventing the development of atrial fibrillation due to its potent atrial-selective inhibition of INa; it induces atrial-selective prolongation of the effective refractory period (ERP) secondary to post-repolarization refractoriness.